Histone deacetylase inhibitors as venetoclax-sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives.
Combining certain drugs can help activate a powerful leukemia treatment in resistant patients, with some achieving complete remission and undetectable disease.
HDAC1/2/3 inhibition has the strongest mechanistic rationale for venetoclax sensitization in AML via MCL-1 suppression; chidamide-based CACAG-VEN achieves ORR 76.5-98%, CRi 73.5-93.3%, MRD-negativity 44-61%, though the isolated HDAC contribution remains unvalidated. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- narrative_review
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- British Journal of Pharmacology
Why it surfaced
Timely translational review for AML (high unmet need); CACAG-VEN response data are clinically compelling; British Journal of Pharmacology; directly addresses resistance to current standard venetoclax + HMA combinations; T1 and T6 watchlist relevance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.